Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses a Phase I study (NCT03870945) aiming to evaluate the efficacy and safety of MB-CART2019.1, a novel CAR-T product, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). This line of treatment was found to have an encouraging safety profile, as no dose-limiting toxicities and very few treatment-emergent adverse events (TEAEs) were reported. Robust and durable CAR-T expansion was seen in the study cohort, with some patients achieving complete remission. Phase II and III studies investigating MB-CART2019.1 are currently underway. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.